Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2003-12-02
2008-12-16
Saoud, Christine (Department: 1649)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007210, C435S007720, C435S007930, C435S069100
Reexamination Certificate
active
07465549
ABSTRACT:
The present invention is drawn to methods of characterization of the properties and functions of SV2 proteins. The invention further includes methods of identifying compounds or agents which modulate the activity of SV2 proteins. Included in these methods is the identification of compounds or agents which modulate the binding of levetiracetam to SV2 proteins, including SV2A. Additionally, the present invention provides biotinylated ligands as a tool to screen chemical libraries and characterize the SV2 proteins. Further, the present invention provides a method of solubilizing and purifying functionally active membrane associated proteins, such as SV2.
REFERENCES:
patent: 2002/0082252 (2002-06-01), Hochman
patent: 2002/0142383 (2002-10-01), Merkulov et al.
patent: 2003/0009024 (2003-01-01), Curtis
patent: 2004/0106147 (2004-06-01), Lynch et al.
patent: WO 01/39779 (2000-11-01), None
patent: WO03016475 (2003-02-01), None
Berkower I. Curr. Opi. Biotech. 1996.7:622-628.
Shorvon et al. J. Neurol. Neurosur. Psych.2002. 72: 426-429.
Mahrhold et al. FEBS Lett. 2006. 580: 2011-4.
Bajjalieh SM, et al. SV2, a brain synaptic vesicle protein homologous to bacterial transporters. Science 1992; 257(5074):1271-1273.
Bajjalieh SM, et al. Brain contains two forms of synaptic vesicle protein 2. Proc Natl Acad Sci (USA). 1993; 90(6):2150-2154.
Bajjalieh SM, et al. Differential expression of synaptic vesicle protein 2 (SV2) isoforms. J Neurosci. 1994 ; 14(9):5223-5235.
Buckley, K et al. Identification of a transmembrane glycoprotein specific for secretory vesicles of neural and endocrine cells. J Cell Biol. 1985; 100(4):1284-1294.
Crowder, KM et al. Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). Proc Natl Acad Sci (USA). 1999; 96(26):15268-15273.
Feany, MB et al. The synaptic vesicle protein SV2 is a novel type of transmembrane transporter. Cell. 1992; 70(5):861-867.
Fuks, B, et al. Localization and photoaffinity labelling of the levetiracetam binding site in rat brain and certain cell lines. European Journal of Pharmacology 478 (2003) pp. 11-19.
Hayashi, M et al. Synaptic vesicle protein SV2B, but not SV2A, is predominantly expressed and associated with microvesicles in rat pinealocytes. Adv Exp Med Biol. 1999; 460:91-93.
Janz, R et al. SVOP, an evolutionarily conserved synaptic vesicle protein, suggests novel transport functions of synaptic vesicles. J Neurosci. 1998; 18(22):9269-9281.
Janz, R et al. SV2A and SV2B function as redundant Ca2+ regulators in neurotransmitter release. Neuron. 1999; 24(4):1003-1016.
Janz, R. Knockout mice and SV2 synaptic-vesicle proteins. University of Texas Health Science Center at Houston Neuroscience Research Center Newsletter, 2001; 7(3):1,4-5.
Lynch B, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. PNAS, Jun. 29, 2004, vol. 101, No. 26, pp. 9861-9866.
Margineanu, DG et al. Levetiracetam: Mehanisms of action. In: Antiepileptic Drugs, 5ht Editiion. Levy,RH et al. eds. 2002; Lippincott Williams & Wilkins, Philadelphia, PA. pp. 419-427.
Noyer, M et al. The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur J Pharmacol. 1995; 286(2):137-146.
Pyle, RA et al. Phosphorylation of synaptic vesicle protein 2 modulates binding to synaptotagmin. J Biol Chem. 2000; 275(22):17195-17200.
Schivell, AE et al. Isoform-specific, calcium-regulated interaction of the synaptic vesicle proteins SV2 and synaptotagmin. J Biol Chem. 1996; 271(44):27770-27775.
Son, Y-J et al. The synaptic vesicle protein SV2 is complexed with an alpha5-containing laminin on the nerve terminal surface. J Biol Chem. 2000; 275(1):451-460.
Xu, T et al. SV2 modulates the size of the readily releasable pool of secretory vesicles. Nat Cell Biol. 2001; 3(8):691-698.
Nagase et al., Prediction of the Coding Sequences of Unidentified Human Genes. XI. The Complete Sequences of 100 New cDNA Clones from Brain Which Code for Large Proteins in vitro. DNA Research 5, 1998, 277-286.
Genbank Accession 094841, May 1, 1999, KIAA0736 Human SV2.
Fuks Bruno
Lynch Berkley
Nocka Karl
Morgan & Lewis & Bockius, LLP
Saoud Christine
UCB S.A.
Wang Chang-Yu
LandOfFree
Methods for identifying agents that bind a levetiracetam... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for identifying agents that bind a levetiracetam..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for identifying agents that bind a levetiracetam... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4024923